Zembrace Symtouch is owned by Upsher Smith Labs.
Zembrace Symtouch contains Sumatriptan Succinate.
Zembrace Symtouch has a total of 2 drug patents out of which 0 drug patents have expired.
Zembrace Symtouch was authorised for market use on 28 January, 2016.
Zembrace Symtouch is available in solution;subcutaneous dosage forms.
Zembrace Symtouch can be used as treatment of migraine.
The generics of Zembrace Symtouch are possible to be released after 29 January, 2036.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10537554 | UPSHER SMITH LABS | Pharmaceutical composition for treating migraine |
Jan, 2036
(13 years from now) | |
US11364224 | UPSHER SMITH LABS | Pharmaceutical composition for treating migraine |
Jan, 2036
(13 years from now) |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 28 January, 2016
Treatment: Treatment of migraine
Dosage: SOLUTION;SUBCUTANEOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic